Agilon Health, INC 8-K filings

agilon health, inc. announced the results of its annual meeting of stockholders held on June 2, 2026, including the election of three Class II directors and the ratification of its independent auditor.

agilon health announced strong first-quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year guidance for total revenues, medical margin, and Adjusted EBITDA.

agilon health has appointed healthcare veteran Tim O'Rourke as its new Chief Executive Officer and President, effective May 7, 2026.

agilon health reported significant losses for fiscal year 2025 but projects a return to breakeven Adjusted EBITDA in 2026 driven by strategic transformation initiatives.

Agilon Health has amended its credit agreement, extending the maturity date of its term loans and revolving credit facility to February 2028, while accepting more restrictive financial covenants and reduced revolving commitments.

Agilon Health, Inc. has updated its Chief Financial Officer Jeffrey Schwaneke's employment agreement, including new equity awards and revised severance terms.

agilon health received a notice from the NYSE for non-compliance with its minimum share price requirement and plans a reverse stock split to regain compliance.

agilon health reports third-quarter 2025 results, revealing a $73 million impact from lower-than-expected risk adjustment revenue and re-establishes its full-year outlook.

Agilon Health reported significant losses in Q2 2025, suspended its full-year guidance, and announced the resignation of its CEO, Steven Sell, replaced by an Office of the Chairman.

Agilon Health, Inc. announced the final voting results from its annual meeting, confirming the election of two Class I directors, the ratification of Ernst & Young LLP as its independent auditor, and the advisory approval of executive compensation.

Agilon Health's Q1 2025 results show a revenue decrease but improved net income, with the company reaffirming its full-year earnings guidance.

Agilon Health's Q4 2024 results show revenue growth but continued losses, prompting strategic actions and a focus on cost discipline for improved 2025 performance.

Agilon Health has entered into new indemnification agreements with its directors and officers and relocated its principal executive office to Westerville, Ohio.

Agilon Health presented at the Wolfe Research Healthcare Conference, detailing strategic actions to improve profitability, strengthen its business, and achieve break-even cash flow by 2027.

Agilon Health's third quarter results show a 28% revenue increase to $1.45 billion, but profitability was negatively impacted by lower-than-expected risk adjustments and higher medical expenses.

Agilon Health's second quarter results show a 39% revenue increase to $1.5 billion, alongside a 38% rise in Medicare Advantage membership, while maintaining its full-year medical margin and adjusted EBITDA guidance.

Agilon Health has appointed Jeff Schwaneke as its new Chief Financial Officer, effective July 1, 2024, succeeding Timothy Bensley who is retiring.

Agilon Health held its annual meeting of stockholders on May 29, 2024, and announced the results of voting on key proposals, including the election of directors and ratification of the company's accounting firm.

Agilon Health's first quarter 2024 results show a 52% revenue increase to $1.6 billion and a 43% rise in Medicare Advantage membership, while maintaining its full-year guidance.

Agilon Health's Q4 2023 revenue increased by 72% to $1.06 billion, but the company experienced a net loss of $230 million due to rising medical costs.

Agilon Health's Chief Medical Officer, Benjamin Kornitzer, M.D., will transition to a strategic advisory role, effective March 1, 2024, with an interim CMO appointed while a permanent replacement is sought.